Dr Gordon Sanghera, CEO and Co-Founder, Oxford Nanopore Technologies plc
LSEG’s Marcus Stuttard speaks to Dr Gordon Sanghera, CEO and Co-Founder of Oxford Nanopore Technologies, about the UK-based biotech company’s route to market and the benefits that has bought them, from credibility amongst global investors to attracting top talent.
As the discussion uncovers, what really sets the business apart is their extraordinary clinical research and scalable technology solutions. Dr Sanghera also explains how Oxford Nanopore has created a revolutionary DNA & RNA sequencing device which will bring huge benefits to humanity in early disease and cancer diagnosis. The very definition of an inspiring company.
-
Marcus Stuttard, Head of UK Primary Markets, Head of AIM, London Stock Exchange
Marcus Stuttard is Head of AIM and has responsibility for Primary Markets in the UK across both AIM and the Main Market. He is responsible for the management and development of AIM, London Stock Exchange’s international growth market for small and medium sized enterprises.He is a regular speaker on growth and business funding issues and sits on a number of industry and policy advisory bodies.
-
Dr Gordon Sanghera, CEO and Co-Founder, Oxford Nanopore Technologies plc
Gordon Sanghera is co-founder of Oxford Nanopore with Spike Willcocks and Hagan Bayley. He was appointed CEO in May 2005 and has led the company through multiple finance rounds, and in 2021, a listing on the London Stock Exchange. The company has developed a new generation of nanopore-based sensing technology. The first products enable the real-time, high-performance, accessible and scalable analysis of DNA and RNA, and this new class of sensing has the potential to expand into proteomics and metabolomics.Fully bespoke manufacturing capability has been built from the ground up, integrating state of the art electronics with silicon fab technology combining the chemistry and biology. The company has been commercially distributing sequencing platforms since 2015, including the handheld and portable MinION and Flongle, and the high-throughput benchtop devices, GridION and PromethION. These platforms are used in more than 100 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments.Dr Sanghera’s PhD in bioelectronic technology was followed by a career at MediSense — an Oxford spin-out that delivered a new generation glucose technology to the market — where he held positions including VP World Wide Marketing, Research Director and Manufacturing Process Development Director. During this time, he was instrumental in the launch of several generations of blood glucose bio-electronic systems for the consumer and hospital medical markets.
